<DOC>
	<DOCNO>NCT01796366</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate safety , tolerability , pharmacokinetics ( exposure trial drug body ) pharmacodynamics ( effect investigate drug body ) NNC0123-0000-0338 ( insulin 338 ) subject type 2 diabetes .</brief_summary>
	<brief_title>A Multiple Dose Trial Investigating Safety , Tolerability , Pharmacokinetics Pharmacodynamics NNC0123-0000-0338 Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Male subject , female subject childbearing potential , surgically sterilize ( i.e . tubal ligation , bilateral oopherectomies ( removal ovary fallopian tube ) hysterectomised ) least 3 month postmenopausal ( i.e . define amenorrhoea least 12 month prior screen document follicle stimulate hormone ( FSH ) level 40 U/L ) Body mass index ( BMI ) 20.0 35.0 kg/m^2 ( inclusive ) Type 2 diabetes mellitus ( diagnose clinically ) 12 month Known suspected hypersensitivity trial product relate product Presence clinically significant acute gastrointestinal symptom ( e.g . nausea , vomit , heartburn diarrhoea ) within 2 week prior dose , judge Investigator Any chronic disorder severe disease opinion Investigator might jeopardise subject 's safety compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>